Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2+ Breast Cancer
NCT03161353Phase 2Active, not recruiting
- Sponsor
- MEDSIR
- Start
- Jun 2017
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of trastuzumab and pertuzumab in HER2-positive breast cancer, sponsored by MEDSIR. Primary endpoints: Pathologic Complete Response at 5.6 months and 3-year Invasive Disease-Free Survival. Started Jun 2017; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03161353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161353.